Better Therapeutics, Inc. (NASDAQ:BTTX) Expected to Post Earnings of -$0.30 Per Share

Equities analysts forecast that Better Therapeutics, Inc. (NASDAQ:BTTXGet Rating) will announce earnings of ($0.30) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Better Therapeutics’ earnings. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Better Therapeutics will report full year earnings of ($2.01) per share for the current year, with EPS estimates ranging from ($2.27) to ($1.77). For the next year, analysts expect that the business will report earnings of ($4.28) per share, with EPS estimates ranging from ($5.32) to ($3.23). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Better Therapeutics.

Better Therapeutics (NASDAQ:BTTXGet Rating) last posted its quarterly earnings data on Monday, March 28th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.25).

Several research analysts have recently commented on the company. Lifesci Capital reiterated an “outperform” rating on shares of Better Therapeutics in a research report on Monday, December 27th. Chardan Capital lifted their target price on Better Therapeutics from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, March 16th.

BTTX stock opened at $1.25 on Monday. The business’s 50 day simple moving average is $2.44. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.26. Better Therapeutics has a 52-week low of $1.18 and a 52-week high of $29.40.

In other Better Therapeutics news, Director Andrew J. Armanino purchased 40,000 shares of the stock in a transaction dated Tuesday, March 29th. The shares were acquired at an average price of $2.14 per share, for a total transaction of $85,600.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders bought a total of 47,500 shares of company stock worth $100,425 in the last three months.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp bought a new stake in shares of Better Therapeutics in the 4th quarter valued at approximately $62,000. Northern Trust Corp bought a new position in Better Therapeutics in the 4th quarter valued at $78,000. D. E. Shaw & Co. Inc. acquired a new position in shares of Better Therapeutics in the 4th quarter valued at $148,000. Finally, Millennium Management LLC acquired a new position in shares of Better Therapeutics in the 4th quarter valued at $318,000. Institutional investors own 76.63% of the company’s stock.

Better Therapeutics Company Profile (Get Rating)

Better Therapeutics, Inc develops prescription digital therapeutics. It is developing Nutritional Cognitive Behavioral Therapy (Nutritional CBT), a behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. Its development pipeline products include BTÂ001 for type2 diabetes; BTÂ002 for Type 2 diabetes with hypertension; BTÂ003 for hypertension; and BTÂ004 for hyperlipidemia.

Recommended Stories

Get a free copy of the Zacks research report on Better Therapeutics (BTTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.